Form 4: Teva Pharma Exec Mark Sabag Reports RSU Vesting

Teva Pharmaceutical Industries Ltd. Executive Vice President Mark Sabag reported the vesting and acquisition of ordinary shares from restricted share units as part of his compensation.

Summary

• Mark Sabag, Executive Vice President, International Markets Commercial for Teva Pharmaceutical Industries Ltd., reported transactions related to his equity compensation.
• On March 4, 2026, Sabag acquired a total of 52,113 ordinary shares (33,512 + 18,601) through the vesting and conversion of Restricted Share Units (RSUs).
• Following these transactions, Sabag directly beneficially owns 271,319 ordinary shares.
• Concurrently, 33,512 RSUs from a March 4, 2022 grant and 18,601 RSUs from a March 4, 2024 grant vested and were converted into ordinary shares.
• Sabag also received a new grant of 30,385 Restricted Share Units on March 4, 2026.
• These new RSUs will vest in tranches: 7,596 units on March 4, 2027, March 4, 2028, and March 4, 2029, and 7,597 units on March 4, 2030.
• After these transactions, Sabag beneficially owns 30,385 new RSUs and 37,202 remaining RSUs from the March 4, 2024 grant (which vest in 2027 and 2028).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event for the executive, reflecting routine compensation and continued alignment with company performance, but it is neutral for the company's immediate operational or financial outlook.

Positives

• Mark Sabag, a key executive, increased his direct beneficial ownership of Teva ordinary shares by 52,113 units, demonstrating continued equity stake in the company.
• The grant of 30,385 new Restricted Share Units aligns executive incentives with long-term shareholder value.

Future Outlook

The filing details future vesting schedules for newly granted Restricted Share Units, indicating continued long-term equity compensation for the executive through March 4, 2030.

Industry Context

StockSavvy.ai notes that equity compensation, particularly through Restricted Share Units, is a standard practice across the pharmaceutical industry to align executive interests with long-term company performance and shareholder value. This filing reflects a routine aspect of executive compensation rather than a strategic shift or operational update.

Stakeholder Impact

• Shareholders: Minor potential dilution from the issuance of new shares upon RSU vesting, offset by the incentive alignment of executive compensation.
• Employees: No direct impact on general employees, but reflects the company's executive compensation structure.
• Executive (Mark Sabag): Increased direct ownership and future equity incentives.

Next Steps

• Future vesting of 18,601 Restricted Share Units on March 4, 2027, and March 4, 2028, from the March 4, 2024 grant.
• Future vesting of 7,596 Restricted Share Units on March 4, 2027, March 4, 2028, and March 4, 2029, from the March 4, 2026 grant.
• Future vesting of 7,597 Restricted Share Units on March 4, 2030, from the March 4, 2026 grant.

Key Dates

Recommendation

This Form 4 filing details routine executive equity compensation through Restricted Share Unit vesting and a new grant. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It primarily confirms ongoing executive incentive alignment.

Keywords

Teva Pharmaceutical Industries, TEVA, Mark Sabag, SEC Form 4, Insider Trading, Restricted Share Units, RSU Vesting, Equity Compensation, Ordinary Shares, American Depositary Shares, Executive Compensation